陆燕

【摘要】 目的：探讨盐酸氨溴索注射液联合溴己新治疗慢性支气管炎患者的效果及对血清炎症因子的影响。方法：选取慢性支气管炎患者98例，随机均分为观察组与对照组。对照组予以溴己新治疗，观察组予盐酸氨溴索注射液联合溴己新治疗，对比两组治疗效果。结果：观察组治疗后呼吸频率、心率均低于对照组，SpO2水平高于对照组（P<0.05）。治疗后，观察组IL-5、IL-8、TNF-α水平均显著低于对照组，差异均有统计学意义（P<0.05）。结论：盐酸氨溴索注射液联合溴己新可有效改善慢性支气管炎患者炎症因子水平，且对心率、呼吸频率影响小，值得推广。

【关键词】 慢性支气管炎 盐酸氨溴索注射液 溴己新 血清炎症因子

doi：10.14033/j.cnki.cfmr.2019.28.072 文献标识码 B 文章编号 1674-6805（2019）28-0-02

Effects of Ambroxol Hydrochloride Injection Combined with Bromhexine on Serum Inflammatory Factors in Patients with Chronic Bronchitis/LU Yan. //Chinese and Foreign Medical Research， 2019， 17（28）： -169

[Abstract] Objective： To investigate the therapeutic effect of Ambroxol Hydrochloride Injection combined with Bromhexine in the treatment of chronic bronchitis and the effect on serum inflammatory factors. Method： A total of 98 patients with chronic bronchitis were randomly divided into the observation group and the control group. The control group was treated with Bromhexine， and the observation group was treated with Ambroxol Hydrochloride Injection combined with Bromhexine. The therapeutic effects of the two groups were compared. Result： After treatment， the respiratory rate and heart rate of the observation group were lower than those of the control group， and the level of SpO2 was higher than that of the control group （P<0.05）. After treatment， the levels of IL-5， IL-8 and TNF-α in the observation group were significantly lower than those of the control group， and the differences were statistically significant （P<0.05）. Conclusion： Ambroxol Hydrochloride Injection combined with Bromhexine can effectively improve the level of inflammatory factors of patients with chronic bronchitis， and have little effect on the heart rate and respiratory rate of patients， which is worthy of promotion.

[Key words] Chronic bronchitis Ambroxol Hydrochloride Injection Bromhexine Serum inflammatory factors

First-authors address： Xiaogan Hospital Affiliated to Wuhan University of Science and Technology， Xiaogan 432000， China

慢性支氣管炎是一种非特异性炎症疾病，临床症状主要有咳嗽、咳痰等，病程长，易反复发作，迁延难愈[1]。同时，还可导致呼吸和血液系统紊乱，加重患者病情[2]。研究证实，溴己新可直接作用于支气管腺体，促进黏液分泌细胞的溶酶体释放，分化和溶解痰中的黏多糖纤维，改善病情，促进气道畅通[3-4]。因此，本研究结合两种药物治疗慢性支气管炎患者，结果报道如下。

1 资料与方法

1.1 一般资料

选取2015年1月-2017年7月于笔者所在医院就诊的慢性支气管炎患者98例。纳入标准：符合《内科学》中慢性支气管炎的诊断标准[5]。排除标准：（1）神经系统疾病;（2）重要脏器功能异常;（3）传染性疾病;（4）造血系统疾病;（5）药物过敏。将患者随机等分为观察组（n=49）与对照组（n=49）。观察组男27例，女22例;年龄33～77岁，平均（53.89±8.52）岁;病程2～17年，平均（10.41±0.86）年。对照组男28例，女21例;年龄35～76岁，平均（54.02±8.66）岁;病程2～18年，平均（10.17±0.81）年。两组一般资料对比，差异均无统计学意义（P>0.05），具有可行性。研究征得医院医学伦理委员会同意，患者及家属均签署知情同意书。